Research Article
Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia
Table 3
Treatment, outcome, and complications in study population.
| | Parameter | Frequency
(%) | -Thal (%)
(%) | -Thal (%)
(%) |
| | Treatment | | | | | Antiplatelet | 26% | 3 (5.6) | 23 (50) | | Iron chelation | 55% | 21 (38.9) | 34 (73.9) | | Splenectomy | 33% | 8 (14.8) | 25 (54.3) | | Complications | | | | | Abnormal plasma glucose | 16% | 9 (16.6) | 7 (15.2) | | Abnormal liver function | 29% | 15 (27.7) | 14 (30.4) | | Cardiomyopathy | 11% | 3 (5.5) | 8 (17.4) | | Cholelithiasis | 35% | 15 (27.7) | 20 (43.5) | | Cholecystectomy | 25% | 10 (18.5) | 15 (32.6) | | EMH | 25% | 3 (5.6) | 22 (47.8) | | Hypothyroidism | 13% | 6 (11.1) | 7 (15.2) | | Hypogonadism | 7% | 2 (3.7) | 5 (10.9) | | Leg ulcers | 2% | 1 (1.8) | 1 (2.2) | | Osteoporosis | 17% | 11 (20.4) | 6 (13.0) | | PHT | 14% | 3 (5.6) | 11 (23.9) | | PXE | None | None | None | | Thrombosis | 4% | 2 (3.7) | 2 (4.3) | | Overall complications | 83% | 43 (79.6) | 40 (87) |
|
|
EMH: extramedullary hematopoiesis, PHT: pulmonary hypertension, PXE: pseudoxanthoma elasticum, -Thal: alpha-thalassemia, and -Thal: beta-thalassemia.
|
